Results 61 to 70 of about 3,437 (189)
HIV Medicine, Volume 26, Issue 8, Page 1184-1198, August 2025.Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Ishfaq Rashid +12 more
wiley +1 more source
, 2010 Objective: To report a potential drug-drug interaction between enfuvirtide, an injectable HIV fusion inhibitor, and niacin in an HIV-infected man with dilated cardiomyopathy.
Elizabeth Oates, Kathryn Dzintars
core +1 more source
Monitoring of Foreign Drug Safety Information
Безопасность и риск фармакотерапии, 2019 Analysis of administrative decisions of foreign regulatory authorities on the recoil of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre ...
Editorial article
doaj +1 more source
Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells
Frontiers in Microbiology, 2020 Infectious diseases caused by human immunodeficiency virus (HIV) and other highly pathogenic enveloped viruses, have threatened the global public health.
Xiaojie Su +5 more
doaj +1 more source
Journal of the International AIDS Society, Volume 28, Issue 7, July 2025.Abstract Introduction Despite its reversal in July 2019, the World Health Organization warning issued in May 2018 of potential teratogenicity associated with dolutegravir (DTG) may have produced persistent sex disparities in access to DTG. We compared DTG uptake of people with HIV (PWH) by sex in Latin America and the Caribbean (LAC) and its potential ...
Fernanda F. Fonseca +15 more
wiley +1 more source
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
Viruses, 2019 Application of highly active antiretroviral drugs (ARDs) effectively reduces morbidity and mortality in HIV-infected individuals. However, the emergence of multiple drug-resistant strains has led to the increased failure of ARDs, thus calling for the ...
Jing Pu +4 more
doaj +1 more source
Latest Progress on Tuberculosis and HIV Co‐Infection: A Closer Look at People of Different Ages
Advanced Therapeutics, Volume 8, Issue 4, April 2025.Tackling the problem of tuberculosis (TB) and human immunodeficiency virus (HIV) co‐infection is a serious global health concern affecting people of all ages. This review presents the characteristics of both diseases, current treatment and diagnostic guidelines, associated problems, innovations in disease management, and overall effects on global ...
Anna Yusuf Aliyu, Oluwatoyin A. Adeleke
wiley +1 more source
Pharmacokinetics‐Based Design of Subcutaneous Controlled Release Systems for Biologics
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 4, Page 668-680, April 2025.ABSTRACT Protein therapeutics have emerged as an exceedingly promising treatment modality in recent times but are predominantly given as intravenous administration. Transitioning to subcutaneous (SC) administration of these therapies could significantly enhance patient convenience by enabling at‐home administration, thereby potentially reducing the ...
Abigail K. Grosskopf +3 more
wiley +1 more source
, 2007 Enfuvirtide is the first of a new class of antiretroviral drugs that inhibits HIV entry. It is a 36 amino acid synthetic peptide that mimics the HR2 region of the HIV-1 gp41, preventing the fusion of viral and cellular membranes.
Bellagamba, R +26 more
core +1 more source
, 2012 Background: For the expression of late viral genes, HIV-1 efficiently exploits the nuclear export by using Rev viral protein, which specifically binds the RNA Rev Responsive Element (RRE). This region is contained within the gp120-gp41 encoding sequence.
Svicher, V +8 more
core +1 more source